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Short Communication
Growth inhibitory effects of interferon on blast cells from
patients with acute myelogenous leukaemia
A.Z.S. Rohatiner
ICRF Department ofMedical Oncology, St. Bartholomew's Hospital, London, ECIA, UK.
The growth inhibitory effect of Interferon was
shown to be dose dependent by Gresser, studying
mouse Interferon and L1210 leukaemia (Gresser et
al., 1970). Similar findings have subsequently been
reported for the antiproliferative activity of human
lymphoblastoid, leukocyte and fibroblast
Interferons on human leukaemic myeloblasts in
short-term liquid culture (Balkwill & Oliver, 1977;
Lundgren et al., 1980).
On the basis of these findings, clinical evaluation
of human lymphoblastoid Interferon (IFN-a) was
undertaken at St. Bartholomew's Hospital in
patients with haematological malignancies. A Phase
I study was performed to determine whether doses
high enough to achieve serum levels known to be
growth inhibitory to myeloblasts in vitro (Balkwill
& Oliver, 1977) could be administered in vivo
(Rohatiner et al., 1982). This having been demon-
strated, a Phase II study of high dose IFN-a,
administered by continuous intravenous infusion
was commenced in patients with acute myelogenous
leukaemia (AML) (Rohatiner et al., 1983).
Myeloblasts from patients with AML who received
IFN in these studies were cultured with different
concentrations of IFN-a to determine whether any
correlation existed between in vitro growth
inhibition and clinical response. The in vitro results
and clinical findings form the basis of this
report.
Myeloblasts were obtained from the bone
marrow (BM) of 23 patients with AML. Nineteen
patients were in relapse and 4 had failed to enter
remission with conventional combination chemo-
therapy. The degree of BM infiltration was >50%
in all patients studied.
IFN-ac (Wellcome Research Laboratories) derived
from the Namalwa lymphoblastoid cell line had a
specific activity of 2.13 x 108unitsmg-1 protein.
Samples of bone marrow were collected into
RPMI 1640 and Heparin (preservative-free,
500unitsml-1). After washing in culture medium
(RPMI 1640 supplemented by 10% foetal calf
serum) the buffy coat was removed and the cells
resuspended at 1 x 106ml-1. Aliquots (0.2ml) were
then incubated in microculture wells at 37°C, in 5%
Co2, 85% humidity, for 3 days. Cells were cultured
alone or with IFN-oa at concentrations of 10, 102,
103 and 104unitsml-1.
Cell growth was assessed by two methods: viable
cells were enumerated using phase contrast
microscopy, 200 cells from each microculture well
being counted after 72h; 0.1 pCi of tritiated
thymidine [3H]dT specific activity 5 Cimmol-1 (The
Radiochemical Centre, Amersham) was added to
each well after 72h. Labelled cells were harvested
and counted after 18 h.
Growth inhibition was expressed as follows:
% reduction in cell no.=
No. cells in IFN containing medium
No. cells in control medium
x 100
% reduction in [3H]dT incorporation=
[3H]dT count from cells in IFN containing medium
[3H]dT count from cells in control medium
x 100
All assays were performed in triplicate and the
mean of three samples taken for each parameter.
IFN-a decreased the number of viable cells and
inhibited the uptake of tritiated thymidine in all
samples (Table I). Inhibition was always dose
dependent, 50% inhibition being observed at IFN
concentrations of 103unitsml-1 in most samples,
although there was considerable between-patient
variability in the degree of growth inhibition
observed at different IFN concentrations.
The mean peak levels of IFN-cx achieved in the
peripheral blood of individual patients in the
clinical studies and the dose received are shown in
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Table I The effect of IFN-a on cell growth and thymidine incorporation in cultures of bone
marrow myeloblasts. Pharmacokinetic and clinical data are included.
Interferon Concentration (unitsml-1)
10 102 103 104 10 102 103 104
Mean peak
% Reduction in Daily IFN serum IFN
% Reduction in [3H]dT dose (x 10-6 level Clinical
Patient cell number incorporation unitsM-2 (unitsml- 1) response
(1) 2 18 42 69 9 15 58 63 5a 103 NE
(2) 0 10 35 53 0 12 42 50 5a 8.5x 102 NE
(3) 3 32 58 84 0 29 54 85 5 2.0 x 102 NR
(4) 0 21 51 65 4 27 46 61 5 2.3 x 102 NR
(5) 7 27 60 85 5 31 65 79 5 3.3 x 102 NE
(6) 0 13 22 45 0 11 33 60 7.5 1.1 x 102 NR
(7) 12 32 54 68 0 27 65 80 10 1.8x 102 NR
(8) 3 24 48 59 0 19 49 62 10 2.7 x 102 NR
(9) 10 28 59 74 5 26 65 80 15 1.1 x 103 NR
decrease in
(10) 0 11 40 62 3 18 54 69 20 4.3 x 103 circulating
blasts
(11) 2 11 26 39 7 19 36 60 20 5.5 x 102 NR
decrease in
(12) 3 19 51 62 11 17 56 70 25 1.3 x 103 circulating
blasts
(13) 12 29 69 85 11 34 89 30 30 3.9 x 103 NR
(14) 4 30 51 66 3 21 56 69 50 3.6x 103 BM 99% to
<5% blasts
(15) 0 18 38 49 2 21 48 62 50 ND NR
(16) 2 10 30 60 0 19 54 78 100 1.3x 103 NE
decrease in
(17) 0 17 47 61 8 17 47 81 100 1.4 x 103 circulating
blasts
(18) 0 28 70 84 6 10 49 59 100 2.7 x 103 NE
(19) 3 19 52 78 0 13 32 56 200 6.4 x 103 NR
(20) 4 29 34 41 14 33 48 66 100 ND NR
(21) 0 1 54 62 13 34 61 78 100 8.5 x 102 NR
(22) 3 35 42 58 12 22 48 55 100 7.6 x 102 NR
(23) 0 2 28 58 7 28 54 69 100 1.07x 103 NR
aFirst 2 patients in the Phase I study received 5 x 106m-2 by i.v. push on 1 and 2 days
respectively.
NR=No response.
NE=Not evaluable for response due to early death.
ND=Not done.
Table I. These studies have been reported in full
elsewhere (Rohatiner et al., 1982; Rohatiner et al.,
1983). It can be seen that there was no correlation
between the serum levels achieved and response or
between the degree of growth inhibition in vitro and
response. However, only patients in whom peak
serum levels > 103unitsml-l were achieved showed
any indication of response, which suggests that
minimum serum levels of 103unitsml-I are
required for any antiproliferative activity in vivo.
These results confirm that IFN has a dose
dependent growth inhibitory effect on human
leukaemic myeloblasts in short term liquid culture,
50% inhibition occurring at an IFN concentration
of 103unitsml-1. This appears to be reversible,
inactivation of the IFN by incubation with trypsin
using the same liquid culture system having been
shown to virtually abrogate the growth inhibitory
effect (Balkwill & Oliver, 1977).
In contrast to the findings with myeloblasts
reported above, when normal bone marrow was
cultured with IFN-a (Balkwill & Oliver, 1977),
thymidine incorporation was suppressed but the
effect on cell survival was less marked.
There was no significant response to therapy in
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achieved during IFN therapy and even above this
level the results were very disappointing.
It is clearly possible that higher concentrations of
IFN might have greater antiproliferative activity
both in vitro and in vivo. However, the achievement
of higher serum levels for prolonged periods is
associated with intolerable toxicity. It must
therefore be concluded from both the in vitro and in
vivo data that high dose infusion IFN therapy will
not play a major part in the primary therapy of
acute myelogenous leukaemia. Whether an
alternative role will be found remains to be seen.
I am indebted to Dr F. Balkwill for her advice and
experience regarding in vitro culture of myeloblasts, and
to Dr T.A. Lister for helpful advice and criticism. I am
grateful to Mr R. Sewell for technical assistance and to
Mrs J. Ashby for preparing the manuscript.
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